We previously developed a dominant-negative peptide, ER α activity-regulator synthetic peptide (ERAP), which specifically disrupts the BIG3-PHB2 interaction and inhibits multiple ERα-signalling pathways driving breast cancer cell growth by reactivating tumour-suppressive activity of PHB210. Here, ESR1 is linked to breast carcinoma.